20.67Average Price Target
The highest estimate is 25.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
This list is an analysis based on recent market events. It's not an investment recommendation.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.
Show more...
FAQ
What is Fortrea stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Fortrea stocks are traded under the ticker FTRE V.
What is Fortrea revenue for the last year?▼
Fortrea revenue for the last year amounts to 2.72B USD.
What is Fortrea net income for the last year?▼
FTRE V net income for the last year is -986.2M USD.
How many employees does Fortrea have?▼
As of August 17, 2026, the company has 14,000 employees.
In which sector is Fortrea located?▼
Fortrea operates in the Health & Wellness sector.
When did Fortrea complete a stock split?▼
Fortrea has not had any recent stock splits.
Where is Fortrea headquartered?▼
Fortrea is headquartered in DURHAM, United States.